Key Takeaways
- Beat and raise, with investment spend: FY26 revenue grew 17% (vs 15% guided) and PAT grew 33% (vs 20% guided), while Q4 EBITDA margin dipped ~90 bps as the company added two new divisions and raised R&D spend.
- Volume leadership is the moat: Corona's 3% volume growth ran at nearly 4.6x the IPM's 0.7%, and new product launches contributed 6.4% growth, almost 2.6x the industry rate.
- Two acquisitions are now live: Wokadine closed on the last day of March, and the Bayer Zydus portfolio relaunch began in Q4, with two arrowhead brands already identified. Both carry margin dilution that management has sized and accepted.
- Biosimilars entry is real and early: Three biosimilar products launched in FY26, including a Semaglutide brand pair targeting what management estimates as a ₹2,000–2,500 crore first-year market.
- What to watch next quarter: Whether the dedicated hormone plant commissions on time in Q1/Q2 FY27, the pace of Wokadine's 400 bps gross margin correction, and any early read on Semaglutide market formation.
Growth Engine: Volume, Pricing & Portfolio
- Volume outperformance is structural: Corona's 3% volume growth vs IPM's 0.7% was driven by therapy leadership and MR productivity, not one-off stocking. Management sees IPM volume growth of 1.5–2% as sustainable for at least a year, which provides a rising floor.
- Pricing power is durable: 7.8% pricing growth is sustainable because 93% of the portfolio is non-NLEM and products are affordable, leaving room for price revision. The non-NLEM share also permits a 10% price hike guideline, while NLEM-linked WPI is under 1%.
- New products are a repeatable lever: New product launches contributed 6.4% to revenue growth, nearly 2.6x the IPM rate of 2.5%. The biosimilars entry and acquired portfolios add fresh launch pipelines for FY27.
- Brand concentration is deepening: Two brands crossed the ₹100 cr milestone, joining a club that now holds two brands in the ₹100–200 cr range and eight brands in the ₹50–100 cr range.
Nirav Mehta: "I was anticipating this since last 6 months, that by November-December, industry will start giving the double-digit growth, and this is sustainable for at least a year, because that has been anticipated in the mind."
Acquisitions: Wokadine & Bayer Zydus Portfolio
- Wokadine closed on the last day of March: The ₹20 cr brand holds the number-2 position in the ₹650+ cr Povidone Iodine market and brings 14 SKUs. Management is focusing on the non-NLEM portion of the portfolio and anticipates 25% revenue growth for at least 3–4 years.
- Wokadine margin dilution is sized: Management expects a 400 bps gross margin correction in the first year, potentially widening to 600–700 bps in later years, because a majority of the SKUs are NLEM. The ₹142.9 cr borrowings on the book are an FD-backed overdraft taken specifically because the deal closed on the last day of March; net cash stands at ₹15 cr.
- Bayer Zydus relaunch is underway: Promotion was slow under the previous owner due to competing priorities, and initial response has been encouraging. Two arrowhead brands have been identified: Menodac (HMG, across four strengths) and Fostine R (Recombinant FSH). A dedicated IVF taskforce was established in Q4 as the fourth focus theme in women's healthcare.
- Portfolio ambition: Management's first target is to scale the acquired portfolio to ₹50–100 cr, with individual brands seen as having potential to become much larger.
Bhavin Bhagat: "I always tell to our investors that we are a net cash company... we don't have any single cash credit facility from any banks. We avail the facility, but we don't use it at the end of the day."
Margin Bridge: Investment Today, Operating Leverage Tomorrow
- Q4 EBITDA margin dipped ~90 bps to 17.6%: The decline was driven by employee cost from the addition of two new divisions (multi-specialty and infertility), higher other expenses related to medical reps, and increased R&D spend. Management frames all three as growth investments.
- Full-year margin still improved: FY26 EBITDA margin rose ~80 bps YoY to 20.9%, showing the underlying business can absorb investment while expanding profitability.
- Gross margin is the anchor: Gross margin stood at 81.4% for FY26, and management expects to sustain it at ~80% going forward, supported by a strong product mix. The B2B export model carries lower gross margin but higher EBITDA margin than the domestic B2C model.
- Margin recovery path: Management expects EBITDA margins to improve through operational effectiveness and cost synergies as revenue grows 15%+. MR productivity rises with tenure, and the new multispecialty division is a restructuring of existing therapy coverage, which should allow faster productivity ramp-up than a greenfield division.
Biosimilars, Manufacturing & International
- Three biosimilar launches in FY26: Fostine R, Tricium DnaB, Wyntide and Tyvenza mark Corona's entry into biosimilars and biologics. The company is open to both organic and inorganic routes (in-licensing/out-licensing) for future biosimilars and complex generics.
- Semaglutide is a large, early bet: Two brands were launched: Wyntide for super-specialist endocrinologists and diabetologists, and Tyvenza for rural and tier-2/3 markets. Management estimates a first-year market of ₹2,000–2,500 crore, based on an addressable patient pool of ~10 crore and a 2–3% conversion rate, with greater clarity expected in 2–3 months. The manufacturing partner is MSM.
- Dedicated hormone plant nearing readiness: The new plant is expected to be operational in Q1 or Q2 of FY27, alongside a 600-kg line expansion already underway.
- International is a slow-burn option: International contribution is high single-digit (8–9%), with 90%+ from India. The Bhayla plant received EAEU GMP certification, opening access to Russia, Belarus, Kazakhstan, Armenia and Kyrgyzstan, but dossier filing and product registration will take ~1.5–2 years, so meaningful revenue is 2–3 years out.
Nirav Mehta: "My own understanding is, and the calculation is if in India there are about 10 crore eligible patients for the Semaglutide market and if conversion ratio is about 2%-3% and the therapy cost, if you calculate, I think the first year may be a year of INR 2,000 crore to INR 2,500 crore as the Semaglutide market."
Sales Force, Productivity & AI Tools
- MR strength is adequate for FY27: Management is comfortable with existing MR strength and does not plan a headcount expansion for the coming year. The new multispecialty division is a restructuring that splits one division into three, not an entirely new therapy build, so productivity ramp can be expedited.
- PCPM rises with tenure: Management described three tenure buckets where productivity increases as reps stay longer, but did not provide a specific timeline for new hires to reach peak productivity when asked.
- AI tools are in deployment: An SFE (Sales Force Effectiveness) tool now provides MRs with daily analytics, and a separate AI tool supports doctors in diagnosis and prescription writing. Both are early-stage productivity plays rather than cost-reduction levers.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Organic revenue growth | 15%+ annually (domestic and international combined) | FY27 and next 3–5 years |
| Acquired portfolio revenue growth | 25% revenue growth on Wokadine and Bayer Zydus portfolio | FY27 and next 2–3 years |
| PAT growth | 20%+ annually | FY27 and next 3–5 years |
| Gross margin floor | Sustain at ~80% | Coming years |
| Wokadine revenue growth | 25% annually | At least 3–4 years |
| Hormone manufacturing plant | Operational | Q1 or Q2 FY27 |
| Myoril long-term loan | Fully repaid | This year (FY27) |
| International Bhayla plant revenue contribution | Product registration takes ~1.5–2 years; meaningful revenue thereafter | 2–3 years out |
Key Metrics
| Metric | Q4 FY26 |
|---|---|
| Revenue | ₹353 cr, +20.2% YoY |
| Domestic revenue growth | 18.3% YoY |
| International revenue growth | 70% YoY |
| EBITDA | ₹62 cr, +14.4% YoY |
| EBITDA margin | 17.6%, declined ~90 bps YoY; impacted by ~₹14 cr in employee-related costs for two new divisions and ~₹1.6 cr in R&D spend |
| PAT | ₹45 cr, +44% YoY |
| FY26 revenue | ₹1,403 cr, +17.3% YoY |
| FY26 EBITDA | ₹293 cr, +22.3% YoY |
| FY26 EBITDA margin | 20.9%, improved ~80 bps YoY |
| FY26 adjusted PAT | ₹199 cr, +33.4% YoY (excluding one-time labour code changes) |
| FY26 gross margin | 81.4% |
| FY26 India business share | 96% of total revenue |
| FY26 chronic segment contribution | 71.9% of revenue |
| FY26 volume growth | 3%, 4.6x IPM volume growth of 0.7% |
| FY26 new product launch growth | 6.4%, 2.6x IPM new product growth of 2.5% |
| FY26 cash flow from operations | ~₹229 cr, CFO to EBITDA conversion at ~78% |
| FY26 RoCE | ~41% |
| FY26 RoE | 29.2% |
| MR strength | 3,100, net addition of 450 in FY26 |
| PCPM | ₹4.11 lakhs per month, up from ₹3.62 lakhs last year |
| Brands in ₹100–₹200 cr club | 2 brands |
| Brands in ₹50–₹100 cr club | 8 brands |
| IPM industry ranking | 27th, improved five spots in last three years |
| FY27 organic revenue growth guidance | 15%+ |
| FY27 acquired portfolio revenue growth guidance | 25% |
| FY27 PAT growth guidance | 20%+ |
| Dividend for FY26 | ₹10 per share, 100% dividend |